TY - JOUR
KW - Invasive pneumococcal disease
KW - Pneumococcal conjugate vaccine
KW - Pneumococcal disease
KW - Pneumococcal pneumonia
KW - United Kingdom
AU - S. Mohanty
AU - B. Podmore
AU - Cuñado Moral
AU - I. Matthews
AU - E. Sarpong
AU - A. Lacetera
AU - N. Qizilbash
AD - Merck & Co., Inc, Center for Observational and Real-World Evidence (CORE), Rahway, NJ, USA. salini.mohanty@merck.com.
OXON Epidemiology Ltd, Epidemiology & Statistics, Madrid, Spain.
MSD (UK) Ltd, Value, Access and Devolved nations (VAD), London, UK.
Merck & Co., Inc., Real-world Data Analytics and Innovation (RDAI), Rahway, NJ, USA.
AN - 36683061
BT - Pneumonia (Nathan)
C2 - PMC9868000
DO - 10.1186/s41479-022-00103-3
DP - NLM
ET - 2023/01/23
LA - eng
M1 - 1
N1 - 2200-6133
Mohanty, Salini
Podmore, Bélène
Cuñado Moral, Ana
Matthews, Ian
Sarpong, Eric
Lacetera, Alessandra
Qizilbash, Nawab
Journal Article
England
Pneumonia (Nathan). 2023 Jan 23;15(1):2. doi: 10.1186/s41479-022-00103-3.
PY - 2023
SN - 2200-6133 (Print)2200-6133
EP - 2
T2 - Pneumonia (Nathan)
TI - Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England
VL - 15
ER -